The final publication is available at Springer via http://dx.doi.org/10.1007/s40292-015-0101-8

ORIGINAL ARTICLE



# A Persian Adaptation of Medication Adherence Self-Efficacy Scale (MASES) in Hypertensive Patients: Psychometric Properties and Factor Structure

Mohsen Saffari<sup>1</sup> · Isa Mohammadi Zeidi<sup>2</sup> · Bengt Fridlund<sup>3</sup> ·
 Hui Chen<sup>4</sup> · Amir H. Pakpour<sup>1,5</sup>

Received: 2 March 2015 / Accepted: 9 May 2015
 © Springer International Publishing Switzerland 2015

#### 9 Abstract

*Introduction* Poor adherence to anti-hypertensive treat ment significantly contributes to the failure to achieve ef fective-controlled blood pressure in patients with
 hypertension.

*Aim* The aim of this study was to convert the original
English version of Medication Adherence Self-efficacy
Scale (MASES) into a Persian version for clinical application in hypertensive patients.

18 Methods The backward-forward translation method was 19 used to produce the Persian version of the questionnaire. 20 Then the internal consistency was assessed using Cron-21 bach's alpha. Exploratory Factor Analysis was applied to 22 extract components of the questionnaire. Correlation be-23 tween blood pressures and drug adherence using MASES 24 was drawn in hypertensive patients.

Results Cronbach's alpha coefficient of the Persian version of MASES was >0.92, suggesting that it can yield consistent results. Exploratory Factor Analysis suggested an unidimensionality of the scale. Patients with

A1	$\bowtie$	Amir H. Pakpour	
	A2	Pakpour_Amir@yahoo.com	

A3	1	Health Research Center, Baqiyatallah University of Medical
A	<b>\</b> 4	Science, Tehran, Iran

- A5 <sup>2</sup> Department of Public Health, Qazvin University of Medical A6 Science, Qazvin, Iran
- A7 <sup>3</sup> School of Health Sciences, Jönköping University, Jönköping,
   A8 Sweden
- A9 <sup>4</sup> School of Life Sciences, Faculty of Science, University of A10 Technology, Sydney, NSW, Australia
- A11 <sup>5</sup> Social Determinants of Health Research Center, Qazvin A12 University of Medical Sciences, Shahid Bahonar Blvd, A13 Qazvin, Iran

uncontrolled hypertension showed poor adherence to hypertensive medications, therefore had significant lower29self-efficacy scores than those with well-controlled blood31pressure by medication.32

ConclusionThe Persian version of MASES is valid and<br/>reliable to assess self-efficacy of anti-hypertension33<br/>34medication adherence in hypertensive patient, which is<br/>helpful to improve medication compliance in such patients35<br/>36in order to achieve better blood pressure control37

**Keyword** Hypertension · Blood pressure control · Self-efficacy

#### 1 Introduction

42 Hypertension is one of the major causes of cerebrovascular and cardiovascular diseases and related mobility and 43 motility. Hypertension is usually a chronic asymptomatic 44 45 condition. It is estimated that worldwide about 60 % of the adult population will develop hypertension in year 2025. 46 Compared to the developed countries, the risk of hyper-47 tension in the developing countries has almost been dou-48 bled, including Iran [1]. Uncontrolled hypertension is 49 defined as systolic blood pressure greater than 140 mmHg 50 or diastolic blood pressure greater than 90 mmHg. How-51 ever, according to the latest recommendation of European 52 53 Society of Hypertension, an ideal target blood pressure is less than 140/85 mmHg [2, 3]. In most cases, lifestyle 54 modification and anti-hypertensive drugs are necessary to 55 maintain an ideal blood pressure in order to reduce the risk 56 of developing cerebrovascular and cardiovascular diseases 57 **[4**]. 58

Only a third of the patients with hypertension have 59 adequate control over their blood pressure levels [5]. 60



Journal : Large 40292	Dispatch : 13-5-2015	Pages : 9
Article No. : 101	□ LE	□ TYPESET
MS Code : BPCP-D-15-00018	🖌 СЬ	🗹 disk

38

39

40

41

1

61 Despite active and intensive drug treatment and increased 62 awareness, the blood pressure in hypertensive patients is 63 still poorly controlled in many countries [6]. Poor adher-64 ence to anti-hypertensive treatment has been shown to 65 significantly contribute to the failure to achieve the goals of blood pressure management in the Seventh Report of the 66 Joint National Committee on Prevention, Detection, 67 68 Evaluation and Treatment of High Blood Pressure, which is 69 unfortunately a global phenomenon [7]. Even with the 70 access to effective anti-hypertensive medications, more 71 than half of the patients spontaneously stopped their 72 medication within the first year after the treatment initiated. 73 Moreover, among the patients who have long-term hyper-74 tension, 50 % of them received more than 80 % of total 75 prescribed medications [8]. As a result of poor adherence to 76 anti-hypertensive medications, approximately 75 % of 77 hypertensive patients cannot achieve good control of their 78 blood pressure [8].

Medication-taking behavior is a complex interaction 79 80 between the biological, psychological and social factors 81 [9]. There are several theories to explain the adherence 82 behavior in hypertensive patients [10, 11]. The theory that 83 is well regarded is the self-efficacy theory. Self-efficacy is 84 defined as the perception of one's ability to complete a 85 take, a goal, or a specific challenge [12]. Self-efficacy has 86 been considered as the most prominent predictor for health 87 related behavioral change, such as adherence to medications in patients with chronic diseases [9]. Hypertensive 88 89 patients with high levels of self-efficacy are more likely to 90 feel confident to adhere to their medications [9, 13].

91 Self-efficacy is a type of self-assessment and self-con-92 fidence to perform a specific task, related to this study, the 93 adherence to hypertensive medications. According to 94 Bandura, it is one of the most important psychological 95 factors that impact on medication adherence [14]. There 96 are increased evidence on the effects of social learning, 97 specifically self-efficacy, on the improvement of adherence 98 over the past two decades [13]. Self-efficacy has been 99 shown to be able to predict medication adherence in indi-100 viduals diagnosed with chronic diseases [9]. McCann and 101 colleagues considered self-efficacy as a "cornerstone of medication adherence" [15]. While there are discrepancy 102 103 in the specific types of self-efficacy for different treat-104 ments, domestic specific self-efficacy is the form that im-105 pacts on the treatment process and outcome [16].

106 Therefore, Ogedegbe and colleagues developed the 107 Medication Adherence Self-Efficacy Scale (MASES) to 108 measure and identify situations in which patients expressed 109 concerns about self-efficacy in adherence to prescribed 110 medications [9]. It is designed to evaluate those who have 111 struggled with blood pressure controls due to poor adher-112 ence to prescribed antihypertensive medications. The de-113 velopment of the MASE was based on the results from open-ended interviews with 106 patients on their experience with anti-hypertensive medications. Responses were 115 divided into nine qualitative categories with 43 questions to 116 cover the barriers and facilitators to medication adherence. 117 MASES can also be used as a research tool to assess the effectiveness of a behavioral intervention program to enhance patients' self-efficacy [9, 17, 18]. 120

Several studies have investigated the medication com-121 pliance among different cohorts of patients in Iran; how-122 123 ever, none of these studies have assessed the medication 124 adherence using MASES, nor in hypertensive patients with uncontrolled blood pressure. Thus, to assess the compli-125 ance of anti-hypertensive medication in Iranian patients 126 with hypertension toward, we need a tool that is compatible 127 with the cultural background. Therefore, this study aimed 128 to, (1) translate the English version of Ogedegbe's MASE 129 into a Persian version, and; (2) examine the reliability and 130 validity in patients with hypertension in Iran. 131

#### 2 Material and Methods 132

## **2.1 Translation of the English Version**133into a Persian Version134

An agreement to translate the original MASE questionnaire 135 was obtained by the authors. The first stage of cultural 136 adaptation was the translation of English questionnaire into 137 Persian language, which was performed by two translators 138 who are native English speakers and fluent in Persian 139 language (forward translation). One of the translators was 140 informed of the objectives and concepts of the question-141 naire, whereas the other one was blind. This stage resulted 142 in two translated versions. The differences between the two 143 144 versions were compared and resolved between the two translators to yield the first final version [19]. 145

The English version of the MASES was again translated146by a native Iranian linguist, who is fluent in English and147was unaware of the purpose of the questionnaire. The148second translator is an Iranian cardiologist who was in-149formed of the objectives of the current study. Both versions150were assessed and consolidated between the researcher and151the translator into a second final version.152

Both final versions were translated back into English by<br/>another two native Persian-speaking translators who are<br/>fluent in English. These two translators did not receive any<br/>information on the concepts and purposes of the ques-<br/>tionnaire. This procedure is the quality control of the ac-<br/>curacy during the translation [19].153<br/>154153<br/>154155155<br/>156156157<br/>158157

Then, the Persian questionnaire was completed by 20 159 hypertensive patients who were randomly selected from 160 those who were excluded from the main study, in order to evaluate and validate the translated questionnaire. The data 162

	[		
E)	Journal : Large 40292	Dispatch : 13-5-2015	Pages : 9
	Article No. : 101	□ LE	□ TYPESET
	MS Code : BPCP-D-15-00018	🛃 СР	🖌 disk

163 of questionnaires were collected anonymously by the au-164 thors for later evaluation. The difficulty level of the Persian 165 questionnaire were then evaluated by a panel of experts in 166 psychology, cardiology, and general practice who are ex-167 perienced in hypertension diagnosis and treatment, as well 168 as five hypertensive patients with different education 169 levels. Based on the assessment outcome, the questionnaire 170 was modified accordingly. In addition, lay language has 171 been used to replace the medical terminology. Subse-172 quently, the final version was again translated from Persian 173 into English by two bilingual translators independently, 174 who were unaware about the original English version of the 175 questionnaire. The discrepancies between the two trans-176 lated versions were again consolidated and the final version 177 of Persian MASE questionnaire was completed for a formal 178 assessment in hypertensive patients who met the selection 179 criteria.

#### 180 2.2 The Evaluation of Validity and Reliability

181 The confidence of the questionnaire was evaluated using 182 internal consistency and re-tests reliability. Cronbach's 183 alpha coefficient was used to assess the internal consis-184 tency [20]. Interpretation of Item-total scale correlation 185 was used to assess the reliability of the questionnaire. 186 These coefficients were only acceptable if the value of the 187 Self-efficacy, the perception of one's ability to complete a 188 task, a goal or a specific challenge (ICC) was greater than 189 0.3 and Cronbach's alpha was equal to or greater than 0.7.

190 The exploratory Factor Analysis was used to assess the 191 factor structure of the questionnaire, and principal com-192 ponent analysis was performed. Several tests were used to 193 assess the suitability of the respondent data before the 194 Factor Analysis, including Kaiser-Meyer-Olkin (KMO) 195 Measure of Sampling Adequacy, and Bartlett's Test of 196 Sphericity. The KMO index is required when the case to 197 variation ratio is less than 1:5. The KMO index is ranged 198 from 0 to 1, with greater than 0.50 considered as suitable 199 for Factor Analysis. The Factor Analysis is only applicable 200 when the Bartlett's Test of Sphericity is significant 201 (P < 0.05). In order to determine the group validity, 202 MASES survey results from patients with well controlled 203 blood pressure were compared with those with uncon-204 trolled hypertension. It was hypothesized that patients with 205 well controlled blood pressure would have higher self-ef-206 ficacy scores than those with uncontrolled blood pressure.

207 Confirmatory Factor Analysis was performed using the 208 statistical software LISREL 8.80. The Model Fitness was evaluated using Chi-square ( $\chi^2$ ), root mean square error of 209 210 approximation (RMSEA), Comparative Fit Index (CFI), 211 and Tucker-Lewis Index (TLI). Model modifications were 212 completed based on modification index and the results of 213 reliability analysis. The criteria used to determine a good Model Fitness were a non-significant Chi-square results, 214 215 the ratio between Chi-square and its degrees of freedom <2.0, the value of TLI and CFI >0.95, and the value of 216 RMSEA <0.06 [21, 22]. 217

#### 2.3 The Use of Persian Version of MASES 218 219 in Hypertensive Patients

This study was conducted in the health centers affiliated to 220 221 Qazvin University of Medical Sciences. This study was approved by the Human Research Ethics Committee of 222 Qazvin University of Medical Sciences. All participants 223 have signed a consent form. 224

Based on the convenience sampling, 184 patients with 225 hypertension who were referred to the health service cen-226 ters in Qazvin were recruited to participate in this study. 227 Inclusive criteria were: 18 years and above, proficient in 228 Persian language (understanding Persian language), lit-229 eracy, using anti-hypertensive drugs for at least a year, 230 volunteered to participate in the study, and have regular 231 follow-up treatments for hypertension. The patients were 232 excluded if they had physical or cognitive disorders or 233 were unwilling to participate. The response rate was 234 95.83 %. Eight patients who were eligible for the study 235 were excluded due to unwillingness to participate. Statis-236 tical tests showed that there was no significant difference 237 between excluded and included patients in terms of socio-238 239 demographic variables.

The MASES developed by Ogedegbe and colleagues [9] 240 has been used to assess the self-efficacy in the adherence to 241 242 anti-hypertensive medications in patients with high mortality risk. The MASES is a patient-centered and self-ad-243 ministered questionnaire that consists of 26 items. The 244 245 patient were asked to rate their confidence of taking antihypertensive medications in different conditions using a 246 three-point scale (1 = unsure, 2 = somewhat sure, and247 3 = very sure). This was performed by trained researchers 248 when the patients were attended in the waiting room before 249 their medical consultations. The total score of the 26 items 250 was then summed up. The score is positively correlated 251 with the level of self-efficacy, with higher score reflecting 252 higher self-efficacy. Original factor structure showed the 253 uni-dimensionality of the scale because the majority of 254 items in this structure were loaded on Factor 1. In addition 255 to the original MASES questions, several questions were 256 257 designed to measure the general characteristics (socio-demographic) of the patient, including age, education, marital 258 status, job status, socioeconomic status, and the number of 259 medications used for controlling hypertension. 260

Blood pressure was measured twice with an interval of 261 10 min for each patient using an automated blood cuff by a 262 general practitioner who was blind to the participants 263 during the measurement. The average of the two 264

Author Proof

$\mathbf{\Sigma}$
-------------------

Journal : Large 40292	Dispatch : 13-5-2015	Pages : 9
Article No. : 101	□ LE	□ TYPESET
MS Code : BPCP-D-15-00018	🗹 СР	🗹 DISK

measurements was used [23]. Patients were resting in a quiet room for 10 min before the first measurement and the measurement was taken under the same condition [24].
Blood pressure was measured by a general practitioner who was blind to the participants. P < 0.05 was considered as significant for all the tests (SPSS 17, Chicago, IL, USA).</li>

#### 271 3 Results

It only took 5 min to complete the questionnaire and the questions are easy to be understood by the patients.
Cronbach's alpha coefficient of the Persian version of the MASES was >0.92, suggesting that this version can yield consistent results over the time (25).
The general characteristics of the participants are shown

The general characteristics of the participants are shown in Table 1. The age range of the participants was between 18 and 73 years old. Most participants in the study were

**Table 1** General characteristics of the sample (n = 184)

Characteristics	Total	Percentage
Age (mean $\pm$ SD)	$61.55 \pm 12.83$	
Gender		
Male	101	54.89
Female	83	45.11
Marital status		
Married	119	64.66
Separated/divorced	17	9.24
Widow	44	23.92
Never married	4	2.18
Education level		
Primary school	84	45.66
High school	85	46.18
University degree	15	8.16
Type of insurance		
Social welfare	98	53.26
Remedial service	58	31.53
Self-paid	22	11.95
No insurance	6	3.26
Employment		
Unemployed	126	68.47
Employed	58	31.53
Economic status		
Low	37	20.11
Middle	83	45.11
Good	55	29.88
Excellent	9	4.90
Duration of hypertension (years)	$6.00\pm4.05$	
Number of medication	$1.34\pm0.85$	
Duration of treatment (years)	$5.3 \pm 3.64$	

married and their education levels were below tertiary<br/>degree. The majority of the patients were covered by the<br/>health insurance. Two thirds of the patients were unem-<br/>ployed, while most of the patients had fair or good eco-<br/>nomic status. The duration of the disease varies between<br/>patients, as well as the number of the medication (Table 1).280<br/>281<br/>282

Table 2 shows the self-efficacy scores, item-to-total 286 correlation, kappa coefficients, and Cronbach's alpha value 287 among 184 patents. Mean self-efficacy scores were ranged 288 from 1.72 to 2.28 with the standard deviations ranged from 289 290 0.51 to 0.81. For all items, kappa values were ranged from 0.28 to 1. The kappa value was less than 0.4 for two items, 291 while it was between 0.4–0.6 for 13 items. There are eleven 292 items with kappa values greater than 0.6. The Cronbach's 293 alpha value was 0.91 for all 26 items. The item-to-total 294 295 correlation coefficients are between 0.248 and 0.685 for all items, which were all acceptable except for the Question 12 296 which reads, "When you are afraid that the medications 297 may affect your sexual performance". Although the item-298 total correlation value for this question was less than 0.3, it 299 was not excluded from the current study. This is because 300 that its Chronbach's alpha value was 0.917 and the removal 301 of this question did not change the internal consistency. In 302 Addition, given that sexual disability is a barrier that is 303 mentioned frequently by the patients, it was retained for its 304 clinical importance, which has also been included in the 305 original MASES by Ogedegbe and coworkers. 306

307 Table 3 shows the factor loadings of each question, Eigen values, and the proportion of total variance against 308 each factor. The KMO Measure value of the data was 309 0.857, which suggests that there was sufficient and high 310 variability in the data to perform component analysis. The 311 results of Bartlett Test of Sphericity (approximate  $\gamma^2$ 312 (325) = 1780.5, P < 0.001) as well as KMO confirmed the 313 factorability of the data. An Exploratory Principal Com-314 ponents Factor Analysis performed on the 26 items in the 315 MASES revealed a five-factor solution using the minimum 316 Eigen value criteria (<1). These five factors contributed to 317 about 67.8 % of the total variance (Table 3). Twenty out of 318 26 items were loaded in Factor 1. Two items were loaded 319 in Factors 2 and 3 and one item was loaded in Factors 4 and 320 5. Six items (6, 15, 17, 19, 23 and 24) had substantial 321 loadings on more than one factor (items with loadings 322 >0.4). Factor loading of all the items were acceptable. 323

The comparisons of Self-efficacy scores between the 324 patients with uncontrolled hypertension and those with 325 well-controlled blood pressure are shown in Table 4. The 326 former had significantly higher systolic (P < 0.05) and 327 diastolic blood pressure (P < 0.05) than the latter 328 (Table 4). The average efficacy score was higher in the 329 patients with controlled blood pressure than those with 330 uncontrolled hypertension (P < 0.05), in 16 out of 26 331 332 questions (Table 4).

Journal : Large 40292	Dispatch : 13-5-2015	Pages : 9
Article No. : 101	□ LE	□ TYPESET
MS Code : BPCP-D-15-00018	CP	M DISK

278

279

Table 2	Item ana	alysis of t	the medication	adherence	self-efficacy	scale
---------	----------	-------------	----------------	-----------	---------------	-------

	Self-efficacy (mean $\pm$ SD)	Kappa coefficients	Cronbach's alpha	ITC
How confident are you in taking your blood pressure medications?				
1. When you are busy at home	$1.92\pm0.73$	0.55	0.918	0.415
2. When you are at work/When you are busy with your daily routines	$1.87\pm0.76$	0.63	0.915	0.507
3. When there is no one to remind you	$2.08\pm0.71$	0.48	0.915	0.506
4. When you worry about taking them for the rest of your life	$1.92\pm0.78$	0.54	0.913	0.580
5. When they cause some side effects	$1.78\pm0.51$	0.47	0.918	0.430
6. When they cost a lot of money	$2.05\pm0.75$	0.46	0.914	0.535
7. When you come home late from work/when your work finishes late	$1.96\pm0.66$	0.72	0.914	0.569
8. When you do not have symptoms	$1.82\pm0.80$	0.46	0.917	0.537
9. When you are with family members	$2.01\pm0.76$	0.61	0.913	0.454
10. When you are in a public area	$1.89\pm0.8$	0.42	0.916	0.551
11. When you are afraid of becoming dependent on them	$1.82\pm0.77$	0.47	0.917	0.484
12. When you are afraid that they may affect your sexual performance	$1.81 \pm 0.77$	0.63	0.917	0.248
13. When the time to take them is between your meals	$2.08 \pm 0.68$	0.65	0.912	0.475
14. When you feel that you don't need them	$1.73\pm0.73$	0.61	0.916	0.622
15. When you are traveling	$1.78 \pm 0.71$	0.78	0.903	0.475
16. When you take them more than once a day	$1.95 \pm 0.72$	1.00	0.916	0.370
17. If they sometimes make you feel tired	$1.81 \pm 0.68$	0.28	0.915	0.485
18. If they sometimes makes you feel dizzy	$1.81 \pm 0.77$	0.57	0.913	0.512
19. When you have other medications to take	$2.04 \pm 0.75$	0.61	0.909	0.570
20. When you feel well	$1.94 \pm 0.83$	0.55	0.917	0.665
21. If they make you want to urinate while away from the toilet	$1.72\pm0.75$	0.65	0.915	0.449
How confident are you that you can carry out the following tasks?				
22. Get refills for your blood pressure medications before they run out	2.28 ± 0.75	0.84	0.915	0.517
23. Fill your prescriptions regardless of the cost	$2.18\pm0.79$	0.45	0.915	0.510
24. Make your medications as part of your daily routine	$2.12\pm0.80$	0.60	0.909	0.685
25. Always remember to take your blood pressure medications	$2.05\pm0.81$	0.29	0.911	0.630
26. Take your blood pressure medications for the rest of your life	$1.96\pm0.83$	0.47	0.916	0.472

ITC item-total scale correlation; SD standard deviation

333 Hypertensive patients also showed lower medication 334 adherence self-efficacy compared with normotensive indi-335 viduals and pre-hypertensive patients (Hypertensive-Nor-336 mal systolic,  $Z_{MWU} = -2.236$ , P = 0.025, Hypertensive-337 Normal systolic,  $Z_{MWU} = -3.025$ , P = 0.002, Hyperten-338 sive-Normal diastolic,  $Z_{MWU} = -2.716$ , P = 0.007, 339 Hypertensive-Normal diastolic,  $Z_{MWU} = -3.147$ , P = 340 0.002, (Table 5).

#### 341 **4 Discussion**

This study modified the English version of MASES into
Persian language, according to the specificity of Iranian
culture. The validity and reliability were confirmed in

individuals with normal blood pressure and hypertensive345patients with/without well controlled blood pressure, where346patients with uncontrolled hypertension had significantly347lower self-efficacy to adhere to anti-hypertensive medica-348tion. The later clearly played a causal role in their uncon-349trolled hypertension.350

The burden of chronic diseases, such as hypertension, is 351 incasing in developing countries [25]. Poor self-efficacy as 352 a contributing factor to increased rate of uncontrolled hy-353 354 pertension shall receive more attention in these countries. Despite the fact that this study was conducted in a devel-355 356 oping country using a modified MASES on the adherence to hypertension treatment, the results are consistent with 357 the studies using the original MASES in developed coun-358 tries, where it has been suggested that non-adherence to 359

Jou Arti

Journal : Large 40292	Dispatch : 13-5-2015	Pages : 9
Article No.: 101	□ LE	□ TYPESET
MS Code : BPCP-D-15-00018	🖌 СР	🖌 disk

#### Table 3 Principal component analysis of the MASES

Item	Factors an	nd loading			
	1	2	3	4	5
1. When you are busy at home	0.673				
2. When you are at work/When you are busy with daily routines	0.677				
4. When you worry about taking them for the rest of your life	0.721				
5. When they cause some side effects	0.703				
6. When they cost a lot of money	0.702			0.493	
7. When you come home late from work/when your daily works finish late	0.741				
8. When you do not have symptoms	0.740				
11. When you are afraid of being dependent on them	0.735				
12. When you are afraid that they may affect your sexual performance	0.775				
13. When the time to take them is between your meals	0.761				
14. When you feel you do not need them	0.691				
15. When you are traveling	0.669				0.533
16. When you take them more than once a day	0.577				
19. When you have other medications to take	0.568				0.466
20. When you feel well	0.577				
21. If they make you want to urinate while away from the toilet	0.677				
23. Fill your prescriptions regardless of the cost	0.718		0.561		
24. Make your blood pressure medications as part of your daily routine	0.729		0.603		
25. Always remember to take your blood pressure medications	0.742				
26. Take your blood pressure medications for the rest of your life	0.773				
9. When you are with family members		0.725			
10. When you are in a public area		0.633			
17. If they sometimes make you feel tired	0.619		0.750		
18. If they sometimes make you feel dizzy	7		0.730		
22. Get refills for your blood pressure medications before they run out				0.759	
3. When there is no one to remind you					0.655
Eigen value	11.12	1.84	1.70	1.56	1.32
% explained variance	42.76	7.09	6.55	6.00	5.41
Cumulative % explained variance	42.76	49.85	56.40	62.40	67.81

anti-hypertensive medication is a key issue in hypertension
management [4, 26]. Therefore, it is necessary to recognize
the poor self-efficacy to antihypertensive medication and
its cause factors, in order to impose behaviour changes in
such patients to improve their blood pressure control.

365 The concept of adherence used in this study is "a per-366 son's behaviours to take anti-hypertensive medications and 367 modify their diet and/or lifestyle correspond to the recommendations by the clinician, according to the guideline 368 369 of the World Health Organization [8]. Adherence to a 370 medication regimen requires a set of behaviors that include 371 obtaining the medication, timely administration of the 372 correct dose via recommended route, and keeping up with 373 the course of the treatment. The importance of adherence to 374 medication is well accepted. However, success in keeping 375 these behaviors can be hampered by many factors related to 376 aging. The loss of sensory function, disturbances of memory and cognition, depression, and lifestyle changes377due to retirement can all disrupt the routine to maintain378regular medication [27–29]. The cessation of medication379can lead to symptom deterioration, increased chance of380hospitalizations, and increased morbidity and mortality381[30, 31].382

As the adherence to anti-hypertensive therapy shall be 383 considered as a precaution of cardiovascular morbidity and 384 mortality, self-efficacy becomes an important factor to 385 assess medication adherence behaviour. However, the as-386 sociation between self-efficacy and adherence to anti-hy-387 pertensive therapy has not been well-characterised in Iran. 388 The current study using a Persian version of the MASE 389 among Iranian patients with hypertension showed that self-390 efficacy is a strong determinant of medication adherence in 391 392 hypertensive patients, which is also closely related to their blood pressure control. 393

**Author Proof** 

스 Adis

•	Journal : Large 40292	Dispatch : 13-5-2015	Pages : 9
	Article No. : 101	□ LE	□ TYPESET
	MS Code : BPCP-D-15-00018	🗹 СР	🖌 disk

 Table 4
 The MASES scores

 between patients with
 uncontrolled hypertension and

 those with well-controlled blood
 blood

pressure

Items	Hypertensive p	Hypertensive patients		
	Uncontrolled	Controlled		
1. When you busy at home	$2.54 \pm 0.64$	$2.75\pm0.61$		
2. When you are at work/When you are busy with daily routines	$2.11\pm0.55$	$2.31\pm0.82$		
3. When there is no one to remind you	$2.83\pm0.81$	$3.00\pm0.00$		
4. When you worry about taking them for the rest of your life	$2.66\pm0.46$	$2.87\pm0.58$		
5. When they cause some side effects	$2.43\pm0.49$	$2.79\pm0.71$		
6. When they cost a lot of money	$2.37\pm0.87$	$2.54 \pm 0.81$		
7. When you come home late from work/when your work finishes late	$2.23\pm0.87$	$2.21 \pm 0.55$		
8. When you do not have symptoms	$2.36 \pm 0.78$	$2.77 \pm 0.63$		
9. When you are with family members	$2.75 \pm 0.60$	$2.75 \pm 0.90$		
10. When you are in a public area	$2.42 \pm 0.57$	$2.80 \pm 0.54$		
11. When you are afraid of becoming dependent on them	$2.77 \pm 0.90$	$3.00 \pm 0.00$		
12. When you are afraid they may affect your sexual performance	$2.39 \pm 0.82$	$2.21 \pm 0.93$		
13. When the time to take them is between your meals	$2.55 \pm 0.64$	$2.76 \pm 0.62$		
14. When you feel you do not need them	$2.63 \pm 0.63$	$2.82 \pm 0.92$		
15. When you are traveling	$2.41 \pm 0.84$	$2.62 \pm 0.76$		
16. When you take them more than once a day	$2.52\pm0.67$	$2.54 \pm 0.70$		
17. If they sometimes make you tired	$2.21 \pm 0.99$	$2.38 \pm 0.00$		
18. If they sometimes makes you feel dizzy	$1.98 \pm 0.53$	$1.83 \pm 0.78$		
19. When you have other medications to take	$2.51 \pm 0.80$	$2.50 \pm 0.63$		
20. When you feel well	$2.43 \pm 0.76$	$2.64 \pm 0.73$		
21. If they make you want to urinate while away from the toilet	$2.33 \pm 0.60$	$2.12 \pm 0.95$		
22. Get refills for your blood pressure medications before they run out	$2.60 \pm 0.49$	$2.44 \pm 0.84$		
23. Fill your prescriptions regardless of the cost	$2.46 \pm 0.54$	$2.63 \pm 0.66$		
24. Make your blood pressure medications as part of your daily routine	$2.81 \pm 0.73$	$2.76 \pm 0.62$		
25. Always remember to take your blood pressure medications	$2.50\pm0.78$	$2.42 \pm 0.95$		
26. Take your blood pressure medications for the rest of your life	$2.71 \pm 0.81$	$2.67 \pm 0.66$		

Table 5         Patients' self-efficacy
AQ1 score for medication adherence
related to blood pressure

	MASES-T				
	N	Total score	Average score of each item	P value	
Systolic blood pressure					
Normal (<120 mmHg)	51	$68.4\pm8.2$	2.62	H value 10.280	
Pre-hypertension (120-139 mmHg)	43	$64.9\pm7.1$	2.57	P = 0.006	
Hypertension (≥140 mmHg)	90	$62.2\pm7.5$	2.50		
Diastolic blood pressure					
Normal (<80 mmHg)	98	$67.5\pm9.2$	2.59	H value 7.125	
Pre-hypertension (80-89 mmHg)	65	$64.8\pm8.6$	2.53	P = 0.028	
Hypertension (≥90 mmHg)	21	$60.3\pm8.4$	2.47		

H statistic (Kruskal Wallis variance analysis)

The self-efficacy, as stated by Bandura, is a self-belief of the ability to perform some difficult tasks, relevant to this study: taking complicated treatment regimens [32]. This can be evaluated by the questions on patient's attitude such as "I can do it", or in hypertensive patients "I can take my anti-hypertensive medication consistently". The latter statement has been evaluated in this study using the Persian MASES. Several studies have suggested the beneficial ef-401fects on health outcomes by the implementing self-efficacy402to continuing treatment programs [33, 34]. However, most403of these studies were on life-threatening infectious dis-404eases, such as HIV infection and chronic viral hepatitis405[35–39]. In addition, in previous studies, self-efficacy has406been correlated with practicing self-care practices for the407

E S
-----

•	Journal : Large 40292	Dispatch : 13-5-2015	Pages : 9	
	Article No. : 101	□ LE	□ TYPESET	
•	MS Code : BPCP-D-15-00018	🖌 СР	🖌 disk	

Author

408 other chronic conditions [40, 41]. This study demonstrated 409 the significant role of self-efficacy in treatment adherence 410 among hypertensive patients, with similar finding as the 411 previous studies [18, 42].

412 The findings of our study obtained from the Principal 413 Component Analysis suggested a structure of one-single 414 factor of the questionnaire. Although a 5-factor structure 415 was vielded, the Factor 1 is the dominant one, and the other four factors could also be easily loaded onto factor 1. Thus 416 the unidimensionality of the Persian MASE is consistent 417 418 with the previous studies using the English MASES [9, 17, 419 18]. Ideally, at least 100–200 patients are required for the Factor Analysis [43]. In our study, 189 patients par-420 421 ticipated, which makes the analysis result acceptable to 422 validate the MASES. This was further confirmed by the 423 comparison between the patients with controlled and un-424 controlled blood pressure. In this study, high value of 425 Cronbach's alpha test was recognized and thus the item 426 redundancy was assessed. Although, several items were 427 closely correlated to each other, there was no redundancy 428 in the other items. This is because that each item refers to different situation, all of which are essential to evaluate the 429 430 attitude towards self-efficacy and practice. The high in-431 ternal consistency in this study suggests the reliability of 432 the questionnaire. Many currently available scales from the 433 other language focus on patient's self-esteem or self-report 434 on the empowerment to take prescribed medication re-435 gardless of patient's concerns [37, 44]. Therefore, the 436 Persian MASES may offer a more holistic approach to 437 determine the self-efficacy in medication adherence than the other measures due to the recognition of the patient's 438 439 perception towards medications.

440 Moreover, based on the present and previous studies, 441 this MASES can distinguish the self-efficacy between hy-442 pertensive patients with controlled and uncontrolled blood 443 pressure. Therefore, it can be used as a tool for the clin-444 icians to monitor their patients' confidence of using anti-445 hypertensive medications. If the patients know little about 446 their health situation and the benefit of the medications, 447 they are less likely to comply to their medications [45]. 448 Therefore, MASES can be a good tool to assess the ef-449 fectiveness of the interventions to reinforce medical 450 knowledge in the patients, in order to increase the self-451 efficacy of the patients to medication adherence [17]. In 452 our study, the patients with uncontrolled hypertension had 453 significantly lower self-efficacy than those with well con-454 trolled blood pressure, which is similar to a previous study 455 in patients with hypertensive histories for more than one 456 year, but not newly diagnosed patients [46]. It has been 457 suggested that the longer duration of the disease could 458 contribute to a higher level of self-efficacy.

There are still some limitations in this study. Firstly,Convenience Sampling was used which may affect the

473

484

501

502

503

504

505

506

507

508

509

510

generality of the results. Further research is needed to use 461 462 random sampling in a larger scale including participants from multiple health centers in Iran. Secondly, our study 463 relied on self-reporting, where certain biases of the patients 464 may affect the final results [47]. Therefore, alternative 465 466 options, such as electronic monitors or more objective reports from the carers, are needed to achieve more accurate 467 information on medication adherence. Finally, the MASES 468 only questioned the current beliefs on medication adher-469 470 ence, where it does not reflect the medical adherence in the 471 past, which may also affect the overall blood pressure control. 472

#### **5** Conclusion

The Persian MASES is useful to improve the evaluation of<br/>confidence in medication adherence among patients with<br/>hypertension. Thus, it can be used as a practical tool to<br/>assess the self-efficacy among Iranian patients with hy-<br/>pertension in medical practice, clinical studies, or clinical<br/>trials.474<br/>475<br/>476

AcknowledgmentsThe authors would like to thank the participants480of the study for sharing their experiences with us. The authors would<br/>also like to thank Miss Mahdieh Pakpour for his constructive help for<br/>data collection.481

#### References

- Kearney PM, et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217–23.
   485 486
- Mancia G, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).
   J Hypertens. 2013;31(7):1281–357.
- Grossman Y, Shlomai G, Grossman E. Treating hypertension in type 2 diabetes. Expert Opin Pharmacother. 2014;15(15):2131–40.
- Krousel-Wood M, et al. Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients. Curr Opin Cardiol. 2004;19(4):357–62.
- Chobanian AV, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206–52.
   Chobanian AV, et al. The seventh report of the Joint National 500
- Chobanian AV, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19): 2560–72.
- Giverhaug T, Falck A, Eriksen BO. Effectiveness of antihypertensive treatment in chronic renal failure: to what extent and with which drugs do patients treated by nephrologists achieve the recommended blood pressure? J Hum Hypertens. 2004;18(9): 649–54.
- 8. Sabaté E. Adherence to long term therapy: evidences for action. Switzerland: World Health Organization; 2003.
- 9. Ogedegbe G, et al. Development and evaluation of a medication<br/>adherence self-efficacy scale in hypertensive African-American<br/>patients. J Clin Epidemiol. 2003;56(6):520-9.511<br/>512<br/>513

	Journal : Large 40292	Dispatch : 13-5-2015	Pages : 9
	Article No. : 101	□ LE	□ TYPESET
• ·	MS Code : BPCP-D-15-00018	🛃 СР	🖌 disk

- 514
  10. Leventhal H, Meyer D, Gutmann M. The role of theory in the study of compliance to high blood pressure regimes. In: Leventhal H, Meyer D, Gutmann M, editors. Patient compliance to prescribed antihypertensive medication regimens: a report to the National Heart, Lung, and Blood Institute. Washington, DC: U.S. Department of Heart and Human Services; 1980.
  11. Dunbar-Jacob J, Dwver EJ, Compliance with antihypertensive
  - Dunbar-Jacob J, Dwyer EJ. Compliance with antihypertensive regimens: a review of the research in the 1980s. Ann Behav Med. 1991;13:32–9.
  - 12. Bandura A. Social foundations of thought and action. Englewood Cliffs: Prentice Hall; 1986.
  - Bosworth H, Oddone E, Weinberger M. Patient treatment adherence: Concepts, interventions and measurement. New York: Lawrence Earlbaum Associates; 2005.
  - 14. Bandura A. Self-efficacy mechanism in human agency. Am Psychol. 1982;97:122.
  - McCann T, Clar E, Lu S. The self-efficacy model of medication adherence in chronic mental illness. J Clin Nurs. 2008;17: 329–40.
  - Bandura A. Self-efficacy: the exercise of control. New York: Wiley; 1994.
  - Gozum S, Hacihasanoglu R. Reliability and validity of the Turkish adaptation of medication adherence self-efficacy scale in hypertensive patients. Eur J Cardiovasc Nurs. 2009;8(2):129–36.
  - Fernandez S, et al. Revision and validation of the medication adherence self-efficacy scale (MASES) in hypertensive African Americans. J Behav Med. 2008;31(6):453–62.
  - 19. Beaton DE, et al. Guidelines for the process of cross-cultural adaptation of self-report measures. Spine (Phila Pa 1976). 2000;25(24):3186–91.
  - Nunnally JC, Bernstein IR. Psychometric theory. 3rd ed. New York: McGraw-Hill; 1994.
  - Bollen KA, Long JS, Models Testing structural equation. Thousand Oaks. CA: Sage Publications; 1993.
  - Hu L, Bentler PM. Cutoff criteria for fit indexes in covariance structure analysis: conventional criteria versus new alternatives. Struct Equ Model. 1999;6:1–55.
- 23. Pickering TG, et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation. 2005;111(5):697–716.
- 557 24. Eguchi K, et al. Consistency of blood pressure differences between the left and right arms. Arch Intern Med. 2007;167(4):388–93.
- 560 25. Koopman JJ, et al. Hypertension in developing countries. Lancet. 2012;380(9852):1471–2.
- 562 26. Bosworth HB, et al. Take Control of Your Blood Pressure (TCYB) study: a multifactorial tailored behavioral and educational intervention for achieving blood pressure control. Patient Educ Couns. 2008;70(3):338–47.
- 566 27. Brown C, et al. Beliefs about antidepressant medications in primary care patients: relationship to self-reported adherence. Med Care. 2005;43(12):1203–7.
- 569 28. Gehi AK, et al. Self-reported medication adherence and cardio-vascular events in patients with stable coronary heart disease: the heart and soul study. Arch Intern Med. 2007;167(16):1798–803.

- Schlenk EA, Dunbar-Jacob J, Engberg S. Medication non-adherence among older adults: a review of strategies and interventions for improvement. J Gerontol Nurs. 2004;30(7):33–43.
- McHorney CA. The adherence estimator: a brief, proximal screener for patient propensity to adhere to prescription medications for chronic disease. Curr Med Res Opin. 2009;25(1):215–38.
- Oyekan E, et al. The B-SMART appropriate medication-use process: a guide for clinicians to help patients—part 1: barriers, solutions, and motivation. Perm J. 2009;13(1):62–9.
   Bandura A, Locke EA. Negative self-efficacy and goal effects
- 32. Bandura A, Locke EA. Negative self-efficacy and goal effects revisited. J Appl Psychol. 2003;88(1):87–99.

582

603

604

605

606

607

613

614

615

616

617

618

619

620

621

622

623

628

629

- 33. Ciere Y, Cartwright M, Newman SP. A systematic review of the mediating role of knowledge, self-efficacy and self-care behaviour in telehealth patients with heart failure. J Telemed Telecare. 2012;18(7):384–91.
  583
  584
  585
  586
- 34. Fors A, et al. The Cardiac Self-Efficacy Scale, a useful tool with potential to evaluate person-centred care. Eur J Cardiovasc Nurs, x02 88 2014.
  35. Louw I Peltzer K Chirinda W Correlates of HIV risk reduction 590
- Louw J, Peltzer K, Chirinda W. Correlates of HIV risk reduction self-efficacy among youth in South Africa. Sci World J. 2012;2012:817315.
   590
- Waldrop-Valverde D, Dong C, Ownby RL. Medication-taking self-efficacy and medication adherence among HIV-infected cocaine users. J Assoc Nurses AIDS Care, 2012.
   593 594 595
- 37. Huang L, et al. Self-efficacy, medication adherence, and quality of life among people living with HIV in Hunan Province of China: a questionnaire survey. J Assoc Nurses AIDS Care, 2012.
  38. Bonner JE, Esserman D, Evon DM, Reliability and validity of a 599
- Bonner JE, Esserman D, Evon DM. Reliability and validity of a self-efficacy instrument for hepatitis C antiviral treatment regimens. J Viral Hepat. 2012;19(5):316–26.
   Grow JM, Christopher SA. Breaking the silence surrounding 602
- 39. Grow JM, Christopher SA. Breaking the silence surrounding hepatitis C by promoting self-efficacy: hepatitis C public service announcements. Qual Health Res. 2008;18(10):1401–12.
- 40. Sharoni SK, Wu SF. Self-efficacy and self-care behavior of Malaysian patients with type 2 diabetes: a cross sectional survey. Nurs Health Sci. 2012;14(1):38–45.
- Warren-Findlow J, Seymour RB, Brunner LR. Huber, The association between self-efficacy and hypertension self-care activities among African American adults. J Community Health. 2012;37(1):15–24.
   Hacihasanoglu R, Gozum S, Capik C, Validity of the Turkish
- 42. Hacihasanoglu R, Gozum S, Capik C. Validity of the Turkish version of the medication adherence self-efficacy scale-short form in hypertensive patients. Anadolu Kardiyol Derg. 2012;12(3):241–8.
- Sapnas KG, Zeller RA. Minimizing sample size when using exploratory factor analysis for measurement. J Nurs Meas. 2002;10(2):135–54.
- 44. Gonzalez JS, et al. The validity of medication adherence selfreports in adults with Type 2 diabetes. Diabetes Care, 2012.
- 45. Park M. Effects of interactive pictorial education on community dwelling older adult's self efficacy and knowledge for safe medication. J Korean Acad Nurs. 2011;41(6):795–804.
- 46. Morris AB, et al. Factors associated with drug adherence and blood pressure control in patients with hypertension. Pharmacotherapy. 2006;26(4):483–92.
  47. Ho LY Lau AS Do self-report measures of social anxiety reflect 627
- 47. Ho LY, Lau AS. Do self-report measures of social anxiety reflect cultural bias or real difficulties for Asian American college students? Cultur Divers Ethnic Minor Psychol. 2011;17(1):52–8.



•	Journal : Large 40292	Dispatch : 13-5-2015	Pages : 9
	Article No. : 101	□ LE	□ TYPESET
	MS Code : BPCP-D-15-00018	🗹 СР	🖌 disk

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550



### Author Query Form

## Please ensure you fill out your response to the queries raised below and return this form along with your corrections

Dear Author

During the process of typesetting your article, the following queries have arisen. Please check your typeset proof carefully against the queries listed below and mark the necessary changes either directly on the proof/online grid or in the 'Author's response' area provided below

Query	Details Required	Author's Response
AQ2	Kindly update the reference [34, 36, 37, 44] with volume and page range if possible.	
AQ1	Both P value and H value are present in last column of Table 5 but the column head is given as P value. Kindly check and amend if necessary.	